The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $1.67 in the prior trading day, Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) closed at $1.45, down -13.17%. In other words, the price has decreased by -$13.17 from its previous closing price. On the day, 0.59 million shares were traded.
Ratios:
Our goal is to gain a better understanding of CYCC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.60 and its Current Ratio is at 5.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 26 ’25 when Lazar David E. sold 194,628,820 shares for $0.03 per share. The transaction valued at 5,507,996 led to the insider holds 0 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3229.07 while its Price-to-Book (P/B) ratio in mrq is 6.14.
Stock Price History:
Over the past 52 weeks, CYCC has reached a high of $39.84, while it has fallen to a 52-week low of $1.36. The 50-Day Moving Average of the stock is -56.85%, while the 200-Day Moving Average is calculated to be -81.87%.
Shares Statistics:
A total of 12.96M shares are outstanding, with a floating share count of 10.41M. Insiders hold about 53.27% of the company’s shares, while institutions hold 0.46% stake in the company.
